Great Basin Scientific Inc (GBSN) 0.07 $GBSN
5 Stocks Under $10 Set to Soar Higher
at The Street - Thu Oct 29, 9:11AM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
SGYP: 6.41 (-0.22), GBSN: 0.07 (+0.01), HLIT: 5.76 (-0.07), LEI: 2.58 (-0.24), CALA: 8.54 (-0.19), MPO: 3.85 (-0.04), FSNN: 2.67 (-0.19), LBIO: 6.47 (-0.14), GNCA: 4.79 (-0.01)
Great Basin Announces Receipt of NASDAQ Notice of Non-Compliance
Business Wire - Tue Oct 20, 3:10PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, today announced that on October 14, 2015, the Company received notice from the NASDAQ Listings Qualifications Staff indicating that the Company did not satisfy the minimum $35 million market value of listed securities and $1.00 bid requirements for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rules 5550(b) and 5550(a) price, respectively (the "Rules"
. In accordance with the NASDAQ Listing Rules, the Company has been provided a grace period of 180 calendar days, through April 11, 2016, to evidence compliance with the Rules. In order to satisfy the Rules, the Company must evidence a market value of listed securities of at least $35 million and a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days (and generally not more than 20 business days) on or before April 11, 2016. The notice has no effect on the listing or trading of the Company's common stock on The NASDAQ Capital Market at this time.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Reports 143 Revenue-Generating Customers to End Third Quarter
Business Wire - Thu Oct 15, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it added 28 new customers in the third quarter of 2015. As of September 30th, the company had secured 143 U.S. customers and had 64 evaluations either in-progress or scheduled, compared to 115 customers and 46 evaluations reported for the second quarter ending June 30, 2015, representing an increase of 24 percent and 39 percent respectively. Great Basin's sales funnel, which represents the number of customers along with active and scheduled customer evaluations, grew to 207 at the end of the third quarter, up from 161 at the end of the second quarter, an increase of 28.5 percent.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Scientific submits Shiga Toxin Direct Test to the US FDA for 510(k) clearance for STEC detection
M2 - Fri Oct 09, 6:10AM CDT
Molecular diagnostics company Great Basin Scientific (NasdaqCM:GBSN) revealed on Thursday that it has submitted its Shiga Toxin Direct Test for the US Food & Drug Administration's (FDA) for 510(k) clearance following the successful completion of a clinical trial that met all of its clinical objectives.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Submits 510(k) Application to the FDA for Shiga Toxin Direct Test
Business Wire - Thu Oct 08, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that the Company has submitted its Shiga Toxin Direct Test to the U.S. Food & Drug Administration (FDA) for 510(k) clearance following the successful completion of a clinical trial that met all of Great Basin's clinical objectives. Upon clearance, the test will be the only stand-alone molecular test to detect Shiga toxin-producing E. coli and the serotype O157 directly from a patient specimen.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Technical Coverage on Financial and Healthcare Stocks - CBOE Holdings, Boston Private, AEterna Zentaris, Great Basin Scientific and Gilead Sciences
PR Newswire - Mon Sep 28, 8:03AM CDT
ACI Association has initiated research coverage on the following equities: CBOE Holdings, Inc. (NASDAQ: CBOE), Boston Private Financial Holdings, Inc. (NASDAQ: BPFH), AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD). On Friday, September 25, 2015, Nasdaq ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
GBSN: 0.07 (+0.01), CBOE: 67.04 (-2.12), GBSNU: 16.22 (-0.28), GILD: 108.13 (-1.08), AEZS: 0.04 (unch), BPFH: 11.46 (-0.26)
Medical Laboratories and Research Stocks Scanner -- Great Basin Scientific, Agilent Technologies, Thermo Fisher Scientific, Exact Sciences, and DexCom
PR Newswire - Thu Sep 24, 7:21AM CDT
Equity Research Institute has initiated coverage on the following equities: Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), Exact Sciences Corporation (NASDAQ: EXAS), and DexCom Inc. (NASDAQ: DXCM). Free research report on Great Basin Scientific can be accessed at https://www.erionline.net/GBSN.pdf On Wednesday, September 23, 2015, the NASDAQ Composite ended at 4,752.74, down 0.08%, the Dow Jones Industrial Average edged 0.31% lower, to finish the day at 16,279.89, and the S&P 500 closed at 1,938.76, down 0.20%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
GBSN: 0.07 (+0.01), DXCM: 83.32 (+0.87), GBSNU: 16.22 (-0.28), TMO: 130.78 (-0.60), A: 37.76 (+0.06), EXAS: 8.33 (+1.18)
Market Coverage on the Healthcare Sector -- AEterna Zentaris, Great Basin Scientific, Gilead Sciences, WaferGen Bio-systems and Horizon Pharma
PR Newswire - Tue Sep 22, 7:27AM CDT
ACI Association has initiated research coverage on the following equities: AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD), WaferGen Bio-systems, Inc. (NASDAQ: WGBS), Horizon Pharma plc (NASDAQ: HZNP). On Monday, September 21, 2015, Nasdaq ended at 4,828.95, up 0.04%, DOW advanced 0.77% to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28), GILD: 108.13 (-1.08), HZNP: 15.72 (-1.77), AEZS: 0.04 (unch), WGBS: 0.90 (-0.02)
Great Basin Announces Retention of Roth Capital Partners as Financial Advisor in Restructuring of the Company's Series C Warrants
Business Wire - Wed Sep 16, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it has retained Roth Capital Partners as financial advisor to assist in a restructuring of the Company's Series C Warrants. The Series C Warrants were issued as part of the Unit offering the Company completed on March 2, 2015. The Company is also preparing to file a proxy statement and hold a special shareholder meeting to seek approval to effect a reverse stock split and authorize additional common shares to meet its obligation to deliver common shares under the cashless exercise provision of the Series C Warrants.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Due Diligence Report: GBSN may be the Dark Horse to Win the Race - BrokerBank Securities
PR Newswire - Mon Sep 14, 7:35AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN) stock has received a strong recommendation of "buy" from two brokerage firm analysts and "hold" from another. Analysts agreed that the short term price target in GBSN is $8.25, but the stock price can fluctuate by $2.47 according to the standard deviation reading.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Scientific to Present at Three Investment Conferences in September
Business Wire - Fri Aug 28, 12:00PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that President and CEO Ryan Ashton and CFO Jeffrey Rona will speak at three upcoming investment conferences in New York City, including:
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Reports 2015 Second Quarter Results and Business Update
Business Wire - Wed Aug 12, 3:02PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN) (NASDAQ:GBSNU), a molecular diagnostic testing company, today reported earnings results for the quarter ended June 30, 2015 and provided a business update.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Announces Upcoming Separation of Publicly Traded Units
Business Wire - Thu Aug 06, 4:30PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that its publicly traded units (the "Units" (symbol: GBSNU) will separate on August 25, 2015, as disclosed in the prospectus dated February 25, 2015, with each Unit separated into its component parts (eight Series C Warrants and one share of Series E Convertible Preferred Stock). In connection with the separation of the Units, the Units will be delisted from The Nasdaq Capital Market effective August 25, 2015.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Announces Business Update Call and Webcast
Business Wire - Wed Aug 05, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that it will report financial results for the second quarter ended June 30, 2015 after the market close on Wednesday, August 12, 2015. The Company also announced that it will host a business update call and webcast to discuss important operational progress and initiatives on the same day at 4:30 PM Eastern Time.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Technical Coverage on Medical Laboratories and Research Stocks -- Laboratory Corp. of America Holdings, DexCom, Bruker, WuXi PharmaTech, and Great Basin Scientific
PR Newswire - Tue Aug 04, 8:35AM CDT
Equity Research Institute has initiated coverage on the following equities: Laboratory Corporation of America Holdings (NYSE: LH), DexCom Inc. (NASDAQ: DXCM), Bruker Corporation (NASDAQ: BRKR), WuXi PharmaTech (NYSE: WX), and Great Basin Scientific Inc. (NASDAQ: GBSN). Free research report on Laboratory Corp. of America Holdings can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=LH On Monday, August 03, 2015, the NASDAQ Composite ended at 5,115.38, down 0.25%, the Dow Jones Industrial Average lost 0.52%, to finish the day at 17,598.20, and the S&P 500 closed at 2,098.04, down 0.28%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
GBSN: 0.07 (+0.01), DXCM: 83.32 (+0.87), BRKR: 18.37 (+0.06), LH: 122.74 (-0.61), WX: 44.70 (+0.10)
SeeThruEquity Initiates Coverage on Great Basin Scientific Inc. (NASDAQ: GBSN) with a Price Target of $9.38
ACCESSWIRE - Mon Jul 27, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / July 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Great Basin Scientific Inc. (NASDAQ: GBSN) with a 12 month price target of $9.38.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin elects Dr. Carlos B. Gonzalez as VP of Engineering
M2 - Thu Jul 16, 6:26AM CDT
Molecular diagnostics company Great Basin Scientific (Nasdaq:GBSN)(Nasdaq:GBSNU) reported on Wednesday the appointment of Dr. Carlos B. Gonzalez, Ph.D. as vice president of its Engineering.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Appoints Dr. Carlos B. Gonzalez as Vice President of Engineering
Business Wire - Wed Jul 15, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that Carlos B. Gonzalez, Ph.D. has joined the Company's management team as Vice President of Engineering. Gonzalez brings more than 20 years of medical device engineering and research experience--including tenure at market leaders such as Abbott and Siemens--to the Utah-based company.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Announces Commercial Launch of Group B Strep Molecular Test
Business Wire - Wed Jul 08, 7:30AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, announced today its Group B Streptococcus (GBS) test--which received U.S. Food and Drug Administration (FDA) clearance in April--is now available to hospitals and laboratories in the U.S. Two laboratories have already converted their Group B Strep testing to Great Basin's molecular test, and as of July 7, more than 40 sites are in active evaluation or scheduled to evaluate the sample-to-result test for GBS. Further, the Company announced its customers evaluating the test are forecasting usage of the GBS test at volumes 50 percent greater than their usage of the Company's C. diff test.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Wins NIH Grant to Develop Direct from Whole Blood Test for Deadly CRE Superbug
Business Wire - Wed Jun 24, 7:30AM CDT
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), has awarded a research grant to Great Basin Scientific (NASDAQ:GBSN; GBSNU) and Brigham Young University (BYU), to develop a rapid molecular diagnostic test direct from whole blood for carbapenem-resistant Enterobacteriaceae (CRE). The NIH research grant (R01AI116989) will play a key role in meeting the goals of President Obama's recent National Action Plan for Combating Antibiotic-Resistant Bacteria.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
5 Stocks Under $10 Set to Soar Higher
at The Street - Thu Oct 29, 9:11AM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
SGYP: 6.41 (-0.22), GBSN: 0.07 (+0.01), HLIT: 5.76 (-0.07), LEI: 2.58 (-0.24), CALA: 8.54 (-0.19), MPO: 3.85 (-0.04), FSNN: 2.67 (-0.19), LBIO: 6.47 (-0.14), GNCA: 4.79 (-0.01)
Great Basin Announces Receipt of NASDAQ Notice of Non-Compliance
Business Wire - Tue Oct 20, 3:10PM CDT
Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, today announced that on October 14, 2015, the Company received notice from the NASDAQ Listings Qualifications Staff indicating that the Company did not satisfy the minimum $35 million market value of listed securities and $1.00 bid requirements for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rules 5550(b) and 5550(a) price, respectively (the "Rules"
. In accordance with the NASDAQ Listing Rules, the Company has been provided a grace period of 180 calendar days, through April 11, 2016, to evidence compliance with the Rules. In order to satisfy the Rules, the Company must evidence a market value of listed securities of at least $35 million and a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days (and generally not more than 20 business days) on or before April 11, 2016. The notice has no effect on the listing or trading of the Company's common stock on The NASDAQ Capital Market at this time. GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Reports 143 Revenue-Generating Customers to End Third Quarter
Business Wire - Thu Oct 15, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it added 28 new customers in the third quarter of 2015. As of September 30th, the company had secured 143 U.S. customers and had 64 evaluations either in-progress or scheduled, compared to 115 customers and 46 evaluations reported for the second quarter ending June 30, 2015, representing an increase of 24 percent and 39 percent respectively. Great Basin's sales funnel, which represents the number of customers along with active and scheduled customer evaluations, grew to 207 at the end of the third quarter, up from 161 at the end of the second quarter, an increase of 28.5 percent.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Scientific submits Shiga Toxin Direct Test to the US FDA for 510(k) clearance for STEC detection
M2 - Fri Oct 09, 6:10AM CDT
Molecular diagnostics company Great Basin Scientific (NasdaqCM:GBSN) revealed on Thursday that it has submitted its Shiga Toxin Direct Test for the US Food & Drug Administration's (FDA) for 510(k) clearance following the successful completion of a clinical trial that met all of its clinical objectives.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Submits 510(k) Application to the FDA for Shiga Toxin Direct Test
Business Wire - Thu Oct 08, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that the Company has submitted its Shiga Toxin Direct Test to the U.S. Food & Drug Administration (FDA) for 510(k) clearance following the successful completion of a clinical trial that met all of Great Basin's clinical objectives. Upon clearance, the test will be the only stand-alone molecular test to detect Shiga toxin-producing E. coli and the serotype O157 directly from a patient specimen.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Technical Coverage on Financial and Healthcare Stocks - CBOE Holdings, Boston Private, AEterna Zentaris, Great Basin Scientific and Gilead Sciences
PR Newswire - Mon Sep 28, 8:03AM CDT
ACI Association has initiated research coverage on the following equities: CBOE Holdings, Inc. (NASDAQ: CBOE), Boston Private Financial Holdings, Inc. (NASDAQ: BPFH), AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD). On Friday, September 25, 2015, Nasdaq ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
GBSN: 0.07 (+0.01), CBOE: 67.04 (-2.12), GBSNU: 16.22 (-0.28), GILD: 108.13 (-1.08), AEZS: 0.04 (unch), BPFH: 11.46 (-0.26)
Medical Laboratories and Research Stocks Scanner -- Great Basin Scientific, Agilent Technologies, Thermo Fisher Scientific, Exact Sciences, and DexCom
PR Newswire - Thu Sep 24, 7:21AM CDT
Equity Research Institute has initiated coverage on the following equities: Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), Exact Sciences Corporation (NASDAQ: EXAS), and DexCom Inc. (NASDAQ: DXCM). Free research report on Great Basin Scientific can be accessed at https://www.erionline.net/GBSN.pdf On Wednesday, September 23, 2015, the NASDAQ Composite ended at 4,752.74, down 0.08%, the Dow Jones Industrial Average edged 0.31% lower, to finish the day at 16,279.89, and the S&P 500 closed at 1,938.76, down 0.20%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
GBSN: 0.07 (+0.01), DXCM: 83.32 (+0.87), GBSNU: 16.22 (-0.28), TMO: 130.78 (-0.60), A: 37.76 (+0.06), EXAS: 8.33 (+1.18)
Market Coverage on the Healthcare Sector -- AEterna Zentaris, Great Basin Scientific, Gilead Sciences, WaferGen Bio-systems and Horizon Pharma
PR Newswire - Tue Sep 22, 7:27AM CDT
ACI Association has initiated research coverage on the following equities: AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD), WaferGen Bio-systems, Inc. (NASDAQ: WGBS), Horizon Pharma plc (NASDAQ: HZNP). On Monday, September 21, 2015, Nasdaq ended at 4,828.95, up 0.04%, DOW advanced 0.77% to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28), GILD: 108.13 (-1.08), HZNP: 15.72 (-1.77), AEZS: 0.04 (unch), WGBS: 0.90 (-0.02)
Great Basin Announces Retention of Roth Capital Partners as Financial Advisor in Restructuring of the Company's Series C Warrants
Business Wire - Wed Sep 16, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it has retained Roth Capital Partners as financial advisor to assist in a restructuring of the Company's Series C Warrants. The Series C Warrants were issued as part of the Unit offering the Company completed on March 2, 2015. The Company is also preparing to file a proxy statement and hold a special shareholder meeting to seek approval to effect a reverse stock split and authorize additional common shares to meet its obligation to deliver common shares under the cashless exercise provision of the Series C Warrants.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Due Diligence Report: GBSN may be the Dark Horse to Win the Race - BrokerBank Securities
PR Newswire - Mon Sep 14, 7:35AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN) stock has received a strong recommendation of "buy" from two brokerage firm analysts and "hold" from another. Analysts agreed that the short term price target in GBSN is $8.25, but the stock price can fluctuate by $2.47 according to the standard deviation reading.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Scientific to Present at Three Investment Conferences in September
Business Wire - Fri Aug 28, 12:00PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that President and CEO Ryan Ashton and CFO Jeffrey Rona will speak at three upcoming investment conferences in New York City, including:
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Reports 2015 Second Quarter Results and Business Update
Business Wire - Wed Aug 12, 3:02PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN) (NASDAQ:GBSNU), a molecular diagnostic testing company, today reported earnings results for the quarter ended June 30, 2015 and provided a business update.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Announces Upcoming Separation of Publicly Traded Units
Business Wire - Thu Aug 06, 4:30PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that its publicly traded units (the "Units"
(symbol: GBSNU) will separate on August 25, 2015, as disclosed in the prospectus dated February 25, 2015, with each Unit separated into its component parts (eight Series C Warrants and one share of Series E Convertible Preferred Stock). In connection with the separation of the Units, the Units will be delisted from The Nasdaq Capital Market effective August 25, 2015. GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Announces Business Update Call and Webcast
Business Wire - Wed Aug 05, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that it will report financial results for the second quarter ended June 30, 2015 after the market close on Wednesday, August 12, 2015. The Company also announced that it will host a business update call and webcast to discuss important operational progress and initiatives on the same day at 4:30 PM Eastern Time.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Technical Coverage on Medical Laboratories and Research Stocks -- Laboratory Corp. of America Holdings, DexCom, Bruker, WuXi PharmaTech, and Great Basin Scientific
PR Newswire - Tue Aug 04, 8:35AM CDT
Equity Research Institute has initiated coverage on the following equities: Laboratory Corporation of America Holdings (NYSE: LH), DexCom Inc. (NASDAQ: DXCM), Bruker Corporation (NASDAQ: BRKR), WuXi PharmaTech (NYSE: WX), and Great Basin Scientific Inc. (NASDAQ: GBSN). Free research report on Laboratory Corp. of America Holdings can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=LH On Monday, August 03, 2015, the NASDAQ Composite ended at 5,115.38, down 0.25%, the Dow Jones Industrial Average lost 0.52%, to finish the day at 17,598.20, and the S&P 500 closed at 2,098.04, down 0.28%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
GBSN: 0.07 (+0.01), DXCM: 83.32 (+0.87), BRKR: 18.37 (+0.06), LH: 122.74 (-0.61), WX: 44.70 (+0.10)
SeeThruEquity Initiates Coverage on Great Basin Scientific Inc. (NASDAQ: GBSN) with a Price Target of $9.38
ACCESSWIRE - Mon Jul 27, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / July 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Great Basin Scientific Inc. (NASDAQ: GBSN) with a 12 month price target of $9.38.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin elects Dr. Carlos B. Gonzalez as VP of Engineering
M2 - Thu Jul 16, 6:26AM CDT
Molecular diagnostics company Great Basin Scientific (Nasdaq:GBSN)(Nasdaq:GBSNU) reported on Wednesday the appointment of Dr. Carlos B. Gonzalez, Ph.D. as vice president of its Engineering.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Appoints Dr. Carlos B. Gonzalez as Vice President of Engineering
Business Wire - Wed Jul 15, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that Carlos B. Gonzalez, Ph.D. has joined the Company's management team as Vice President of Engineering. Gonzalez brings more than 20 years of medical device engineering and research experience--including tenure at market leaders such as Abbott and Siemens--to the Utah-based company.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Announces Commercial Launch of Group B Strep Molecular Test
Business Wire - Wed Jul 08, 7:30AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, announced today its Group B Streptococcus (GBS) test--which received U.S. Food and Drug Administration (FDA) clearance in April--is now available to hospitals and laboratories in the U.S. Two laboratories have already converted their Group B Strep testing to Great Basin's molecular test, and as of July 7, more than 40 sites are in active evaluation or scheduled to evaluate the sample-to-result test for GBS. Further, the Company announced its customers evaluating the test are forecasting usage of the GBS test at volumes 50 percent greater than their usage of the Company's C. diff test.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
Great Basin Wins NIH Grant to Develop Direct from Whole Blood Test for Deadly CRE Superbug
Business Wire - Wed Jun 24, 7:30AM CDT
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), has awarded a research grant to Great Basin Scientific (NASDAQ:GBSN; GBSNU) and Brigham Young University (BYU), to develop a rapid molecular diagnostic test direct from whole blood for carbapenem-resistant Enterobacteriaceae (CRE). The NIH research grant (R01AI116989) will play a key role in meeting the goals of President Obama's recent National Action Plan for Combating Antibiotic-Resistant Bacteria.
GBSN: 0.07 (+0.01), GBSNU: 16.22 (-0.28)
